

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

mt

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification</b> <sup>6</sup> : <b>C12Q 1/68, C07K 16/8</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/12758</b> <b>(43) International Publication Date:</b> 9 March 2000 (09.03.00)
<b>(21) International Application Number:</b> PCT/US99/19655 <b>(22) International Filing Date:</b> 1 September 1999 (01.09.99) <b>(30) Priority Data:</b> 60/098,880 2 September 1998 (02.09.98) US <i>02 Mar 01 / 30 May</i> <b>(71) Applicant (for all designated States except US):</b> DIADEX US LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> <del>SALCEDA</del> , Susana [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US); <del>SUN</del> , Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US); <del>RECIPON</del> , Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US); <del>CAFFERKEY</del> , Robert [IE/US]; Apartment 218, 350 Elan Village Lane, San Jose, CA 95134 (US). <b>(74) Agents:</b> LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).		<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS		
<b>(57) Abstract</b>  The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.		

THIS PAGE BLANK (USPTO)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THIS PAGE BLANK (USPTO)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : C12Q 1/68; C07K 16/8 US CL : 435/6, 7.1, 7.92; 530/387.1, 388.85 According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 7.1, 7.92; 530/387.1, 388.85 .. Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEQ ID NO's 1-5 and 9-14 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Medline, CAPLUS, GenEmbl, N-Geneseq, USPATFULL														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X ---P Y	US 5,939,258 A (CROCE et al) 17 August 1999, see col. 3, lines 1-22.	1-3 ----- 4,5												
X ----- Y	US 5,733,748 A ( YU et al) 31 March 1998, see abstract.	1-3 ----- 4, 5												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*&amp;* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 22 NOVEMBER 1999		Date of mailing of the international search report 07 FEB 2000												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer LARRY HELMS Telephone No. (703) 308-0196												

THIS PAGE BLANK (USPTO)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PAOLONI-GIACOBNO et al. Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCR Domains and Maps to 21q22.3. Genomics. 1997, Vol. 44, pages 309-320, especially page 311.	1-9

THIS PAGE BLANK (USPTO)



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-9

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-9, drawn to an in vitro method for diagnosing the presence of cancer by measuring the CSG levels in a patient with an antibody against CSG.

Group II, claim(s) 10-11, drawn to a method of in vivo imaging a selected cancer by administering an antibody with a paramagnetic ion or radioisotope label to the patient.

Group III, claim(s) 12-13, drawn to a method of in vivo treating a cancer in a patient comprising administering an antibody conjugated to a cytotoxic agent.

The inventions listed as Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The method of Group I recites the special technical feature of an in vitro diagnostic method to measure CSG levels that are not found in Groups II and III. The method of Group II recites the special technical features of an in vivo imaging method that is not found in Groups I and III. The method of Group III recites the special technical feature of in vivo treating a cancer using a cytotoxic agent that is not found in Groups I and II. Therefore, inventions of Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1.

**THIS PAGE BLANK (USPTO)**

**A NOVEL METHOD OF DIAGNOSING,  
MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS**

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed  
5 assays for detecting, diagnosing, monitoring, staging,  
prognosticating, imaging and treating various cancers,  
particularly gynecologic cancer including ovarian, uterine  
endometrial and breast cancer, and lung cancer.

**BACKGROUND OF THE INVENTION**

10 The American Cancer Society has estimated that over  
560,000 Americans will die this year from cancer. Cancer is  
the second leading cause of death in the United States,  
exceeded only by heart disease. It has been estimated that  
over one million new cancer cases will be diagnosed in 1999  
15 alone.

In women, gynecologic cancers account for more than one-  
fourth of the malignancies.

Of the gynecologic cancers, breast cancer is the most  
common. According to the Women's Cancer Network, 1 out of  
20 every 8 women in the United States is at risk of developing  
breast cancer, and 1 out of every 28 women are at risk of  
dying from breast cancer. Approximately 77% of women  
diagnosed with breast cancer are over the age of 50.  
However, breast cancer is the leading cause of death in women  
25 between the ages of 40 and 55.

Carcinoma of the ovary is another very common  
gynecologic cancer. Approximately one in 70 women will  
develop ovarian cancer during her lifetime. An estimated  
14,500 deaths in 1995 resulted from ovarian cancer. It causes  
30 more deaths than any other cancer of the female reproductive  
system. Ovarian cancer often does not cause any noticeable

symptoms. Some possible warning signals, however, are an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40; rarely there will be abnormal vaginal bleeding.

- 5 Periodic, complete pelvic examinations are important; a Pap test does not detect ovarian cancer. Annual pelvic exams are recommended for women over 40.

Also common in women is endometrial cancer or carcinoma of the lining of the uterus. According to the Women's Cancer  
10 Center endometrial cancer accounts for approximately 13% of all malignancies in women. There are about 34,000 cases of endometrial cancer diagnosed in the United States each year.

Uterine sarcoma is another type of uterine malignancy much more rare as compared to other gynecologic cancers. In  
15 uterine sarcoma, malignant cells start growing in the muscles or other supporting tissues of the uterus. Sarcoma of the uterus is different from cancer of the endometrium, a disease in which cancer cells start growing in the lining of the uterus. This uterine cancer usually begins after menopause.  
20 Women who have received therapy with high-dose X-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus. These X-rays are sometimes given to women to stop bleeding from the uterus.

Lung cancer is the second most prevalent type of cancer  
25 for both men and women in the United States and is the most common cause of cancer death in both sexes. Lung cancer can result from a primary tumor originating in the lung or a secondary tumor which has spread from another organ such as the bowel or breast. Primary lung cancer is divided into  
30 three main types; small cell lung cancer; non-small cell lung cancer; and mesothelioma. Small cell lung cancer is also called "Oat Cell" lung cancer because the cancer cells are a distinctive oat shape. There are three types of non-small cell lung cancer. These are grouped together because they behave  
35 in a similar way and respond to treatment differently to small

cell lung cancer. The three types are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Squamous cell cancer is the most common type of lung cancer. It develops from the cells that line the airways. Adenocarcinoma also develops from the cells that line the airways. However, adenocarcinoma develops from a particular type of cell that produces mucus (phlegm). Large cell lung cancer has been thus named because the cells look large and rounded when they are viewed under a microscope. Mesothelioma is a rare type of cancer which affects the covering of the lung called the pleura. Mesothelioma is often caused by exposure to asbestos.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating each of these types of cancer are of critical importance to the outcome of the patient. In all cases, patients diagnosed early in development of the cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with a cancer which has metastasized. New diagnostic methods which are more sensitive and specific for early detection of various types of cancer are clearly needed.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo* imaging and treating selected cancers including, but not limited to, gynecologic cancers such as ovarian, breast endometrial and/or uterine cancer, and lung cancer via detection of a Cancer Specific Genes (CSGs). Nine CGSs have been identified and refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by the nine CSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4,

5, 6, 7, 8 or 9. Fragments of the CSGs such as those depicted in SEQ ID NO:10, 11, 12, 13 or 14 can also be detected.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the selected cancer. For the purposes of this invention, by "selected cancer" it is meant to include gynecologic cancers such as ovarian, breast, endometrial and uterine cancer, and lung cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having a selected cancer which is not known to have metastasized by identifying a human patient suspected of having a selected cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient



versus the normal human control is associated with a cancer which has metastasized.

Also provided by the invention is a method of staging selected cancers in a human patient by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring selected cancers in patients for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in stage of selected cancers in humans having such cancer by looking at levels of CSG. The method comprises identifying a human patient having a selected cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of

CSG is associated with a cancer which is regressing or in remission.

Further provided are antibodies against CSG or fragments of such antibodies which can be used to detect or image  
5 localization of CSG in a patient for the purpose of detecting or diagnosing selected cancers. Such antibodies can be polyclonal or monoclonal, or prepared by molecular biology techniques. The term "antibody", as used herein and  
10 throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals.  
15 These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a CSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug  
20 or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the  
25 specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and  
30 from reading the other parts of the present disclosure.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating selected

cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by levels of CSG as used herein is levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by levels of CSG as used herein is levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels of the gene comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. Fragments of CSGs such as those depicted in SEQ ID NO: 10, 11, 12, 13 and 14 can also be detected. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of CSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of selected cancers. What is meant by "selected cancers" as used herein is a gynecologic cancer such as ovarian, breast, endometrial or uterine cancer, or lung case.

Any of the 9 CSGs can be measured alone in the methods of the invention, or all together or any combination thereof. However, for methods relating to gynecologic cancers including ovarian, breast, endometrial and uterine cancer, it is preferred that levels of CSG comprising SEQ ID NO:1 or a fragment thereof be determined. Exemplary fragments of this CSG which can be detected are depicted in SEQ ID NO: 10, 11, 12, and 13. For methods relating to lung cancer and gynecologic cancers including ovarian, endometrial and uterine, it is preferred that levels of CSG comprising SEQ ID NO:2 or 9 be determined. Fragments of this CSG such as that depicted in SEQ ID NO:14 can also be detected. For methods relating to ovarian cancer, determination of levels of CSG comprising SEQ ID NO:3 is also preferred.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

### ***Diagnostic Assays***

The present invention provides methods for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the presence of a selected cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastases of selected cancers in a patient having a selected cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having a selected cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of ovarian cancer, patients are typically diagnosed with ovarian cancer following surgical staging and monitoring of CA125 levels. Traditional detection methods are also available and well known for other selected cancers which can be diagnosed by determination of CSG levels in a patient.

In the present invention, determining the presence of CSG levels in cells, tissues or bodily fluid, is particularly useful for discriminating between a selected cancer which has not metastasized and a selected cancer which has metastasized.

5 Existing techniques have difficulty discriminating between cancers which have metastasized and cancers which have not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels  
10 measured in such cells, tissues or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is CSG in serum, this level is preferably compared with the level of CSG in serum  
15 of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with a cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating  
20 the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily  
25 fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may also include samples from  
30 a human patient that is determined by reliable methods to have a selected cancer which has not metastasized.

### **Staging**

The invention also provides a method of staging selected cancers in human patients. The method comprises identifying  
35 a human patient having a selected cancer and analyzing a

sample of cells, tissues or bodily fluid from such human patient for CSG. Then, the method compares CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a  
5 normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

#### 10 **Monitoring**

Further provided is a method of monitoring selected cancers in humans for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing  
15 a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human  
20 patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of selected cancers in humans having such cancers. The method comprises identifying a human  
25 patient having a selected cancer; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human  
30 control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

## 5 **Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include  
10 radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein  
15 in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds  
20 specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to CSG is  
25 incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds  
30 to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG.  
35 Unattached reporter antibody is then washed out. Reagents for

peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to CSG attached to a solid support and labeled CSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods may be used to detect CSG mRNA as a marker for selected cancers. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of the various selected malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon



or plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

5 Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be  
10 done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

15 Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.  
20 First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on  
25 the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or  
30 subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue  
35 extracts (homogenates or solubilized tissue) such as from

tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.

#### 5 ***In Vivo Antibody Use***

Antibodies against CSG can also be used *in vivo* in patients suspected of suffering from a selected cancer including lung cancer or gynecologic cancers such as ovarian, breast, endometrial or uterine cancer. Specifically,  
10 antibodies against a CSG can be injected into a patient suspected of having a selected cancer for diagnostic and/or therapeutic purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use  
15 in the radioimmunoscinotographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin.  
20 Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSGs can be used in a similar manner. Labeled antibodies against a CSG can be  
25 injected into patients suspected of having a selected cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or  
30 Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can used in magnetic resonance imaging (MRI).  
35 Localization of the label permits determination of the spread

of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with a selected cancer, injection  
5 of an antibody against a CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been  
10 described in the art for example by Garnett and Baldwin, *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. *Cell* 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have  
15 been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares *Cancer Supplement* 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of  
20 antibodies against CSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded  
25 oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

The present invention is further described by the following examples. These examples are provided solely to  
30 illustrate the invention by reference to specific embodiments. The exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

**EXAMPLES****Example 1:**

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

The CLASP performs the following steps: selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs; analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease. Selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor libraries. The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the CSGs selection.

**Table 1: CSG Sequences**

SEQ ID NO:	Clone ID	Gene ID
1	16656542	234617
2	1283171	332459
3	1649377	481154
4	236044H1	none assigned
5	none assigned	255687
6	none assigned	251313
7	none assigned	12029
8	none assigned	251804

The following examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail.

Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

**Example 2: Relative Quantitation of Gene Expression**

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene for every example in normal and cancer tissue were evaluated. Total RNA was extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700

Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

**Measurement of Ovr110; Clone ID16656542; Gene ID 234617 (SEQ ID NO:1, 10, 11, 12 or 13)**

The absolute numbers depicted in Table 2 are relative levels of expression of Ovr110 (SEQ ID NO:1 or a fragment thereof as depicted in SEQ ID NO:10, 11, 12, or 13) in 12 normal different tissues. All the values are compared to normal stomach (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

**Table 2: Relative Levels of Ovr110 Expression in Pooled Samples**

15	Tissue	NORMAL
	colon	0.00
	endometrium	8.82
	kidney	7.19
	liver	0.36
20	ovary	1.19
	pancreas	21.41
	prostate	2.79
	small intestine	0.03
	spleen	0.00
25	00000000000000stoma	1.00
	testis	8.72
	uterus	0.93

The relative levels of expression in Table 2 show that Ovr110 is expressed at comparable levels in most of the normal tissues analyzed. Pancreas, with a relative expression level of 21.41, endometrium (8.82), testis (8.72), and kidney (7.19) are the only tissues expressing high levels of Ovr110 mRNA.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of Ovr110 in 73 pairs of matching samples. All the values are compared to normal stomach (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 15 unmatched cancer samples (from ovary and mammary gland) and 14 unmatched normal samples (from ovary and mammary gland) were also tested.

**Table 3: Relative Levels of Ovr110 Expression in Individual Samples**

Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
Ovr103X	Ovary 1	86.22	0.53	
Ovr10400	Ovary 2	168.31		
Ovr1157	Ovary 3	528.22		
Ovr63A	Ovary 4	1.71		
Ovr7730	Ovary 5	464.65		
Ovr10050	Ovary 6	18.32		
Ovr1028	Ovary 7	7.78		
Ovr1118	Ovary 8	0.00		
Ovr130X	Ovary 9	149.09		
Ovr638A	Ovary 10	3.14		
OvrA1B	Ovary 11	21.26		
OvrA1C	Ovary 12	1.83		
OvrC360	Ovary 13	0.52		
Ovr18GA	Ovary 14			1.07
Ovr20GA	Ovary 15			1.88
Ovr25GA	Ovary 16			2.52
Ovr206I	Ovary 17			2.51
Ovr32RA	Ovary 18			3.01

	Ovr35GA	Ovary 19			5.17
	Ovr40G	Ovary 20			0.45
	Ovr50GB	Ovary 21			2.69
	OvrC087	Ovary 22			0.47
5	OvrC179	Ovary 23			1.46
	OvrC004	Ovary 24			4.99
	OvrC007	Ovary 25			13.36
	OvrC109	Ovary 26			6.61
	MamS516	Mammary Gland 1	16.39	13.74	
10	MamS621	Mammary Gland 2	826.70	4.60	
	MamS854	Mammary Gland 3	34.60	18.30	
	Mam59X	Mammary Gland 4	721.57	27.00	
	MamS079	Mammary Gland 5	80.73	5.10	
	MamS967	Mammary Gland 6	6746.90	72.80	
15	MamS127	Mammary Gland 7	7.00	20.00	
	MamB011X	Mammary Gland 8	1042.00	29.00	
	Mam12B	Mammary Gland 9	1342.00		
	Mam82XI	Mammary Gland 10	507.00		
	MamS123	Mammary Gland 11	24.85	4.24	
20	MamS699	Mammary Gland 12	84.74	5.54	
	MamS997	Mammary Gland 13	482.71	11.84	
	Mam162X	Mammary Gland 14	15.73	10.59	



	MamA06X	Mammary Gland 15	1418.35	8.20	
	Mam603X	Mammary Gland 16	294.00		
	Mam699F	Mammary Gland 17	567.40	86.60	
	Mam12X	Mammary Gland 18	425.00	31.00	
5	MamA04	Mammary Gland 19			2.00
	Mam42DN	Mammary Gland 20	46.05	31.02	
	Utr23XU	Uterus 1	600.49	27.95	
	Utr85XU	Uterus 2	73.52	18.83	
	Utr135XO	Uterus 3	178.00	274.00	
10	Utr141XO	Uterus 4	289.00	26.00	
	CvxNKS54	Cervix 1	2.47	0.61	
	CvxKS83	Cervix 2	1.00	2.00	
	CvxNKS18	Cervix 3	1.00	0.00	
	CvxNK23	Cervix 4	5.84	14.47	
15	CvxNK24	Cervix 5	20.32	33.13	
	End68X	Endometrium 1	167.73	544.96	
	End8963	Endometrium 2	340.14	20.89	
	End8XA	Endometrium 3	1.68	224.41	
	End65RA	Endometrium 4	303.00	5.00	
20	End8911	Endometrium 5	1038.00	74.00	
	End3AX	Endometrium 6	6.59	1.69	
	End4XA	Endometrium 7	0.43	15.45	

	End5XA	Endometrium 8	17.81	388.02	
	End10479	Endometrium 9	1251.60	31.10	
	End12XA	Endometrium 10	312.80	33.80	
	Kid107XD	Kidney 1	2.68	29.65	
5	Kid109XD	Kidney 2	81.01	228.33	
	Kid10XD	Kidney 3	0.00	15.30	
	Kid6XD	Kidney 4	18.32	9.06	
	Kid11XD	Kidney 5	1.38	20.75	
	Kid5XD	Kidney 6	30.27	0.19	
10	Liv15XA	Liver 1	0.00	0.45	
	Liv42X	Liver 2	0.81	0.40	
	Liv94XA	Liver 3	12.00	2.16	
	Lng LC71	Lung 1	5.45	3.31	
	LngAC39	Lung 2	1.11	0.00	
15	LngBR94	Lung 3	4.50	0.00	
	LngSQ45	Lung 4	15.03	0.76	
	LngC20X	Lung 5	0.00	1.65	
	LngSQ56	Lung 6	91.77	8.03	
	ClnAS89	Colon 1	0.79	7.65	
20	ClnC9XR	Colon 2	0.03	0.00	
	ClnRC67	Colon 3	0.00	0.00	
	ClnSG36	Colon 4	0.81	0.35	
	ClnTX89	Colon 5	0.00	0.00	
	ClnSG45	Colon 6	0.00	0.06	
25	ClnTX01	Colon 7	0.00	0.00	
	Pan77X	Pancreas 1	0.89	2.62	
	Pan71XL	Pancreas 2	3.99	0.12	
	Pan82XP	Pancreas 3	59.92	28.44	
	Pan92X	Pancreas 4	17.21	0.00	

	StoAC93	Stomach 1	7.54	6.43	
	StoAC99	Stomach 2	19.49	3.19	
	StoAC44	Stomach 3	3.62	0.37	
	SmI21XA	Small Intestine 1	0.00	0.00	
5	SmIH89	Small Intestine 2	0.00	0.00	
	Bld32XK	Bladder 1	0.00	0.21	
	Bld46XK	Bladder 2	0.36	0.32	
	BldTR17	Bladder 3	0.28	0.00	
	Tst39X	Testis	11.24	2.24	
10	Pro84XB	Prostate 1	2.60	24.30	
	Pro90XB	Prostate 2	1.40	2.00	

0.00= Negative

Table 2 and Table 3 represent a combined total of 187 samples in 16 different tissue types. In the analysis of matching samples, the higher levels of expression were in mammary gland, uterus, endometrium and ovary, showing a high degree of tissue specificity for the gynecologic tissues. Of all the samples different than those mentioned before analyzed, only a few samples (Kid109XD, LngSQ56, and Pan82XP) showed high levels of expression of Ovr110.

Furthermore, the level of mRNA expression was compared in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Ovr110 in 15 of 16 mammary gland cancer tissues compared with their respective normal adjacent (mammary gland samples MamS516, MamS621, MamS854, Mam59X, MamS079, MamS967, MamB011X, MamS123, MamS699, MamS997, Mam162X, MamA06X, Mam699F, Mam12X, and Mam42DN).

There was overexpression in the cancer tissue for 94% of the mammary gland matching samples tested.

For uterus, Ovr110 is overexpressed in 3 of 4 matching samples (uterus samples Utr23XU, Utr85XU, and Utr141XO). There  
5 was overexpression in the cancer tissue for 75% of the uterus matching samples analyzed.

For endometrium, Ovr110 is overexpressed in 6 of 10 matching samples (endometrium samples End8963, End65RA, End8911, End3AX, End10479, and End12XA). There was  
10 overexpression in the cancer tissue for 60% of the endometrium matching samples.

For ovary, Ovr110 shows overexpression in 1 of 1 matching sample. For the unmatched ovarian samples, 8 of 12 cancer samples show expression values of Ovr110 higher than  
15 the median (2.52) for the normal unmatched ovarian samples. There was overexpression in the cancer tissue for 67% of the unmatched ovarian samples.

Altogether, the level of tissue specificity, plus the mRNA overexpression in most of the matching samples tested are  
20 indicative of Ovr110 (including SEQ ID NO:1, 10, 11, 12 or 13) being a diagnostic marker for gynecologic cancers, specifically, mammary gland or breast, uterine, ovarian and endometrial cancer.

**Measurement of Ovr114; Clone ID1649377; Gene ID 481154 (SEQ  
25 ID NO:3)**

The numbers depicted in Table 4 are relative levels of expression in 12 normal tissues of Ovr114 compared to pancreas (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue  
30 from different individuals.

Table 4: Relative Levels of Ovr114 Expression in Pooled Samples

	Tissue	Normal
5	Colon	2.3
	Endometrium	7.6
	Kidney	0.5
	Liver	0.6
	Ovary	5.2
	Pancreas	1.0
10	Prostate	2.1
	Small Intestine	1.3
	Spleen	2.4
	Stomach	1.5
	Testis	15.8
15	Uterus	8.8

The relative levels of expression in Table 4 show that Ovr114 mRNA expression is detected in all the pools of normal tissues analyzed.

The tissues shown in Table 4 are pooled samples from 20 different individuals. The tissues shown in Table 5 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 4 cannot be directly compared to the values shown in Table 5.

The numbers depicted in Table 5 are relative levels of 25 expression of Ovr114 compared to pancreas (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 5: Relative Levels of Ovr114 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	17.04		3.93
Ovary 2	OvrG021SPI/SN2	Papillary serous adenocarcinoma	1.62		4.34
Ovary 3	OvrG010SP/SN	Papillary serous adenocarcinoma	0.50		1.12
Ovary 4	OvrA081F/A082D	Mucinous tumor, low malignant potential		0.84	0.96
Ovary 5	OvrA084/A086	Mucinous tumor, grade G-B, borderline		5.24	6.00
Ovary 6	Ovr14604A1C	Serous cystadenofibroma, low malignancy		5.33	
Ovary 7	Ovr14638A1C	Follicular cysts, low malignant potential		8.11	
Ovary 8	Ovr10400	Papillary serous adenocarcinoma, G2	13.27		
Ovary 9	Ovr11570	Papillary serous adenocarcinoma	106.08		
Ovary 10	Ovr10050	Papillary serous endometrioid carcinoma	77.04		
Ovary 11	Ovr10280	Ovarian carcinoma	14.78		
Ovary 12	Ovr14603A1D	Adenocarcinoma	22.23		

Ovary 13	Ovr9410C360	Endometrioid adenocarcinoma	4.74		
Ovary 14	Ovr1305X	Papillary serous adenocarcinoma	96.49		
Ovary 15	Ovr7730	Papillary serous adenocarcinoma	8.40		
Ovary 16	Ovr988Z	Papillary serous adenocarcinoma	6.40		
Ovary 17	Ovr9702C018GA	Normal Cystic			12.06
Ovary 18	Ovr2061	Normal left atrophic, small cystic			10.11
Ovary 19	Ovr9702C020GA	Normal-multiple ovarian cysts			12.70
Ovary 20	Ovr9702C025GA	Normal-hemorrhage CL cysts			22.09
Ovary 21	Ovr9701C050GB	Normal-multiple ovarian cysts			9.01
Ovary 22	Ovr9701C087RA	Normal-small follicle cysts			1.86
Ovary 23	Ovr9702C032RA				7.81
Ovary 24	Ovr9701C109RA	Normal			1.50
Ovary 25	Ovr9411C057R	Benign large endometriotic cyst			5.22
Ovary 26	Ovr9701C179a	Normal			3.09
Ovary 27	Ovr14610	Serous cystadenofibroma, no malignancy			3.53
Ovary 28	Ovr9701C035GA	Normal			6.32

Ovary 29	Ovr9702C007RA	Normal				0
Ovary 30	Ovr9701C087RA	Normal-small follicle cysts				1.97
Ovary 31	Ovr9411C109	Normal				9.49
Ovary 32	Ovr9701C177a	Normal-cystic follicles				3.85
Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	1.30			0.70
Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	1.83			11.90
Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	13.32			7.76
Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	3.62			3.34
Mammary Gland 1	Mam00042D01/N01		3.13			0.76
Mammary Gland 2	MamS99-522A/B		4.45			0.45
Mammary Gland 3	Mam1620F/1621F		0.74			1.91
Mammary Gland 4	Mam4003259a/g		3.48			2.00
Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	46.96			11.96
Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	20.02			5.90
Uterus 3	Utr13590/13580	Tumor/NAT	10.23			7.74
Uterus 4	Utr14170/14180	Malignant tumor/NAT	7.52			4.92

5

10

15

20



Cervix 1	CvxVNM00083/83	Keratinizing squamous cell carcinoma	5.47	14.31
Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	4.99	3.99
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	10.14	14.22
Bladder 1	Bld665T/664T		1.43	4.03
Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	1.15	0.99
Kidney 1	Kid4003710C/F		0.03	0.35
Kidney 2	Kid1242D/1243D		1.61	0.14
Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	2.44	5.73
Lung 2	Lng8890A/8890B	Cancer/NAT	1.11	5.19
Lung 3	Lng9502C109R/10R		1.99	0.80
Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.67	1.07
Liver 2	LivVNM00175/175	Cancer/NAT	15.46	2.85
Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	2.83	0.70
Skin 2	Skn4005287A1/B2		0.91	4.02
Small Int. 1	SmI9802H008/009		0.87	0.82
Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT	0.81	1.22
Stomach 2	StoS9822539A/B	Adenocarcinoma/NAT	1.22	1.39

5

10

15

Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor	0.47	0.35
Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	2.39	2.61
Prostate 2	Pro1094B/1095B		0.10	0.38
Pancreas 1	Pan776p/777p	Tumor/NAT	2.39	0.52
Pancreas 2	Pan824p/825p	Cystic adenoma	1.66	1.22
Testis 1	Tst239X/240X	Tumor/NAT	1.24	1.72
Colon 1	Cln9706c068ra/69 ra	Adenocarcinoma/NAT	0.38	0.65
Colon 2	Cln4004732A7/B6	Adenocarcinoma/NAT	0.44	1.26
Colon 3	Cln4004695A9/B8		1.94	1.53
Colon 4	Cln9612B006/005	Asc. Colon, Cecum, adenocarcinoma	3.38	1.10
Colon 5	Cln9704C024R/25R	Adenocarcinoma/NAT	1.66	2.77

Table 4 and Table 5 represent a combined total of 129 samples in 17 human tissue types. Among 117 samples in Table 5 representing 16 different tissues high levels of expression are seen only in ovarian cancer samples. The median expression of Ovr114 is 14.03 (range: 0.5 - 106.08) in ovarian cancer and 4.34 (range: 0 - 22.09) in normal ovaries. In other words, the median expression levels of Ovr114 in cancer samples is increased 3.5 fold as compared with that of the normal ovarian samples. Five of 12 ovarian cancers (42%) showed increased expression relative to normal ovary (with 95% specificity). The median expression of Ovr114 in other gynecologic cancers is 4.99, and 2 out of 15 samples showed expression levels comparable with that in ovarian cancer. The median of the expression levels of Ovr114 in the rest of the cancer samples is 1.24, which is more than 11 fold less than that detected in ovarian cancer samples. No individual showed an expression level comparable to that of ovarian cancer samples (except Liver 2; LivVNM00175/175).

The 3.5 fold increase in expression in 42% of the individual ovarian cancer samples and no compatible expression in other non-gynecologic cancers is indicative of Ovr114 being a diagnostic marker for detection of ovarian cancer cells. It is believed that the Ovr114 marker may also be useful in detection of additional gynecologic cancers.

**Measurement of Ovr115; Clone ID1283171; Gene ID 332459 (SEQ ID NO:2 or 14)**

The numbers depicted in Table 6 are relative levels of expression Ovr115 compared to their respective calibrators. The numbers are relative levels of expression in 12 normal tissues of ovaries compared to Testis (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue from different individuals.

**Table 6: Relative Levels of Ovr115 Expression in Pooled Samples**

	<b>Tissue</b>	<b>Normal</b>
5	Colon	858.10
	Endometrium	12.34
	Kidney	3.76
	Liver	0.00
	Ovary	0.43
	Pancreas	0.00
10	Prostate	8.91
	Small Intestine	62.25
	Spleen	0.00
	Stomach	37.53
	Testis	1.00
15	Uterus	47.67

The relative levels of expression in Table 6 show that Ovr115 mRNA expression is detected in all the 12 normal tissue pools analyzed.

The tissues shown in Table 6 are pooled samples from 20 different individuals. The tissues shown in Table 7 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 6 cannot be directly compared to the values shown in Table 7.

The numbers depicted in Table 7 are relative levels 25 of expression of Ovr115 compared to testis (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 7: Relative Levels of Ovr115 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	193.34		0.24
Ovary 3	OvrG021SPI/SN2	Papillary serous adenocarcinoma	0.38		0.31
Ovary 4	OvrG010SP/SN	Papillary serous adenocarcinoma	231.25		0.45
Ovary 2	OvrA084/A086	Mucinous tumor, grade G-B, borderline		143.34	16.65
Ovary 5	OvrA081F/A082D	Mucinous tumor, low malignant potential		314.13	0
Ovary 19	Ovr14604A1C	Serous cystadenofibroma, low malignancy		299.87	
Ovary 26	Ovr14638A1C	Follicular cysts, low malignant potential		1278.32	
Ovary 6	Ovr10400	Papillary serous adenocarcinoma, G2	144.25		
Ovary 22	Ovr9410C360	Endometrioid adenocarcinoma	0.29		
Ovary 23	Ovr1305X	Papillary serous adenocarcinoma	157.41		
Ovary 27	Ovr7730	Papillary serous adenocarcinoma	340.04		
Ovary 28	Ovr988Z	Papillary serous adenocarcinoma	464.75		

Ovary 7	Ovr11570	Papillary serous adenocarcinoma	432.07		
Ovary 8	Ovr10050	Papillary serous endometricarcinoma	74.23		
Ovary 9	Ovr10280	Ovarian carcinoma	1408.79		
Ovary 10	Ovr14603A1D	Adenocarcinoma	0.00		
Ovary 11	Ovr9702C018GA	Normal Cystic			0.16
Ovary 12	Ovr2061	Normal left atrophic, small cystic			0.00
Ovary 13	Ovr9702C020GA	Normal-multiple ovarian cysts			0.00
Ovary 14	Ovr9702C025GA	Normal-hemorrhage CL cysts			0.00
Ovary 15	Ovr9701C050GB	Normal-multiple ovarian cysts			0.91
Ovary 16	Ovr9701C087RA	Normal-small follicle cysts			0.00
Ovary 17	Ovr9702C032RA				0.28
Ovary 18	Ovr9701C109RA	Normal			0.00
Ovary 20	Ovr9411C057R	Benign large endometriotic cyst			38.87
Ovary 21	Ovr9701C179a	Normal			0.08
Ovary 24	Ovr14610	Serous cystadenofibroma, no malignancy			0.00
Ovary 25	Ovr9701C035GA	Normal			0.00
Ovary 29	Ovr9702C007RA	Normal			0.00

5

10

15

Ovary 30	Ovr9701C087RA	Normal-small follicle cysts			0.00
Ovary 31	Ovr9411C109	Normal			0.00
Ovary 32	Ovr9701C177a	Normal-cystic follicles			0.00
Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	39.95		13.60
Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	140.37		22.67
Uterus 3	Utr13590/1358)	Tumor/NAT	16.45		32.50
Uterus 4	Utr14170/14180	Malignant tumor/NAT	288.52		5.29
Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	2.61		6.24
Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	2.10		49.40
Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	480.77		19.22
Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	322.07		31.08
Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	38.81		7.36
Lung 2	Lng8890A/8890B	Cancer/NAT	690.12		14.71
Lung 3	Lng9502C109R/10R		1756.90		2.86
Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	10.56		0.00
Skin 2	Skn4005287A1/B2		331.30		47.23
Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	14.64		4.39

5

10

15

Prostate 2	Pro1094B/1095B		0.09		2.54
Bladder 1	Bld665T/664T		404.56		90.20
Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	77.35		177.37
Kidney 1	Kid4003710C/F		0.17		12.72
Kidney 2	Kid1242D/1243D		0.00		13.74
Mammary Gland 1	Mam1620F/1621F		0.27		0.12
Mammary Gland 2	Mam4003259a/g		5.71		0.00
Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.14		0.69
Liver 2	LivVNM00175/175	Cancer/NAT	0.00		0.00
Small Int. 1	SmI9802H008/009		128.44		151.38
Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT	303.01		116.72
Stomach 2	StoS9822539A/B	Adenocarcinoma/NAT	24.12		17.76
Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor	0.00		9.10
Pancreas 1	Pan776p/777p	Tumor/NAT	0.00		0.43
Pancreas 2	Pan824p/825p	Cystic adenoma	0.00		3.17
Testis 1	Tst239X/240X	Tumor/NAT	24.05		1.37
Colon 1	ClN9706c068ra/69ra	Adenocarcinoma/NAT	605.60		169.77
Colon 2	ClN4004732A7/B6	Adenocarcinoma/NAT	367.20		281.32

5

10

15

20



Colon 3	Cln4004695A9/B8		316.15		295.77
Colon 4	Cln9612B006/005	Asc. Colon. Cecum, adenocarcinoma	820.89		543.52
Colon 5	Cln9704C024R/25R	Adenocarcinoma/NAT	161.18		150.07
Cervix 1	CvxVNM00083/83	Keratinizing squamous cell carcinoma	738.17		1195.88
Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	1473.04		1229.80
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	2877.48		1275.02

Table 6 and Table 7 represent a combined total of 129 samples in 17 human tissue types. Comparisons of the level of mRNA expression in ovarian cancer samples and the normal adjacent tissue from the same individuals or normal tissues from other individuals are shown in Table 7. Ovr115 was expressed at higher levels in 9 of 12 cancer tissues (75%), relative to the maximum level detected in all 21 normal or normal adjacent ovarian samples. All 4 of 4 (100%) ovarian tumors with borderline malignancy had elevated Ovr115 expression. The median expression in ovarian cancers (including the ones with borderline malignancy) was 212.30 while the median expression in normal ovaries was 0. When compared with their own normal adjacent tissue samples, expression levels of Ovr115 were also elevated in 3 of 3 (100%) lung cancers, 3 of 4 (75%) uterus cancers and 2 of 4 (50%) endometrial cancers.

The relatively high expression levels of Ovr115 in ovarian and other selected cancer samples is indicative of Ovr115 being a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer.

A homolog of Ovr115 has also been identified in public data base; g2597613 as gi|2507612|gb|U75329.1|HSU75329 Human serine protease mRNA, complete CDS. This homolog is depicted herein as SEQ ID NO:9. It is believed that SEQ ID NO:9 or the protein encoded thereby (SEQ ID NO:15) may also be useful as a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer in human patients.

**What is claimed is:**

1. A method for diagnosing the presence of a selected cancer in a patient comprising:
  - (a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and
  - 5 (b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CSG in said patient versus normal human control is associated with the presence of a selected cancer.
- 10 2. A method of diagnosing metastases of a selected cancer in a patient comprising:
  - (a) identifying a patient having a selected cancer that is not known to have metastasized;
  - (b) measuring CSG levels in a sample of cells, tissues,
  - 15 or bodily fluid from said patient; and
  - (c) comparing the measured CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer
  - 20 which has metastasized.
3. A method of staging a selected cancer in a patient having the selected cancer comprising:
  - (a) identifying a patient having the selected cancer;
  - (b) measuring CSG levels in a sample of cells, tissue,
  - 25 or bodily fluid from said patient; and
  - (c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control sample, wherein an increase in measured CSG levels in said patient versus the normal human control is associated with a
  - 30 cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

4. A method of monitoring a selected cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

(b) periodically measuring levels of CSG in samples of  
5 cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the  
10 normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of a selected cancer in a patient comprising:

(a) identifying a patient having a selected cancer;

15 (b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the  
20 normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG  
25 comprises SEQ ID NO:1, 10, 11, 12 or 13 and the selected cancer is a gynecologic cancer selected from the group consisting of breast, ovarian, endometrial and uterine cancer.

7. The method of claim 1, 2, 3, 4 or 5 wherein the CSG  
comprises SEQ ID NO:2, 9 or 14 and the selected cancer is lung  
30 cancer or a gynecologic cancer selected from the group consisting of ovarian, endometrial and uterine cancer.

8. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14 and the selected cancer is ovarian cancer.

9. An antibody against a CSG wherein said CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14.

5        10. A method of imaging a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

11. The method of claim 10 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10        12. A method of treating a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

13. The method of claim 12 wherein the antibody is conjugated to a cytotoxic agent.



THIS PAGE BLANK (USPTO)



## SEQUENCE LISTING

<110> Salceda, Susana  
Sun, Yongming  
Recipon, Herve  
Cafferkey, Robert  
DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,  
IMAGING AND TREATING VARIOUS CANCERS

<130> DEX-0043

<140>

<141>

<150> 60/098,880

<151> 1998-09-02

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 2587

<212> DNA

<213> Homo sapiens

<400> 1

```
ggaaggcagc gggcagctcc actcagccag tacccagata cgctgggaac cttccccagc 60
catggcttcc ctggggcaga tcctcttctg gagcataatt agcatcatca ttattctggc 120
tggagcaatt gcactcatca ttggctttgg tatttcaggg agacactcca tcacagtcac 180
tactgtcgcc tcagctggga acattgggga ggatggaatc ctgagctgca cttttgaacc 240
tgacatcaaaa ctttctgata tcgtgataca atggctgaag gaagggtgtt taggcttggg 300
ccatgagttc aaagaaggca aagatgagct gtcggagcag gatgaaatgt tcagaggccg 360
gacagcagtg tttgctgatc aagtgatagt tggcaatgcc tctttgcggc tgaaaaacgt 420
gcaactcaca gatgctggca cctacaaatg ttatatcatc acttctaaag gcaaggggaa 480
tgctaacctt gagtataaaa ctggagcctt cagcatgccg gaagtgaatg tggactataa 540
tgccagctca gagaccttgc ggtgtgaggc tccccgatgg ttccccagc ccacagtggg 600
ctgggcatcc caagttgacc agggagccaa cttctcggaa gtctccaata ccagctttga 660
gctgaactct gagaatgtga ccatgaagggt tgtgtctgtg ctctacaatg ttacgatcaa 720
caacacatac tcctgtatga ttgaaaatga cattgccaaa gcaacagggg atatcaaagt 780
gacagaatcg gagatcaaaa ggcggagtca cctacagctg ctaaaactcaa aggcttctct 840
gtgtgtctct tctttctttg ccatcagctg ggcacttctg cctctcagcc cttacctgat 900
gctaaaataa tgtgccttgg ccacaaaaaa gcatgcaaag tcattgttac aacagggatc 960
tacagaacta tttcaccacc agatatgacc tagttttata tttctgggag gaaatgaatt 1020
catatctaga agtctggagt gagcaacaa gagcaagaa caaaaagaag ccaaaagcag 1080
aaggctccaa tatgaacaag ataaatctat cttcaaagac atattagaag ttgggaaaaat 1140
```



THIS PAGE BLANK (USPTO)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100



aattcatgtg aatagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag 1200  
tgcattccca gatctcaggg acctccccct gcctgtcacc tggggagtga gaggacagga 1260  
tagtgcattg tctttgtctc tgaattttta gttatatgtg ctgtaatgtt gctctgagga 1320  
agcccttga aagtctatcc caacatatcc acatcttata tccacaaat taagctgtag 1380  
tatgtacct aagacgtgc taattgactg ccacttcgca actcaggggc ggctgcattt 1440  
tagtaatggg tcaaagtatt cactttttat gatgcttcca aaggtgcctt ggcttctctt 1500  
cccaactgac aaatgccaaa gttgagaaaa atgatacataa ttttagcata aacagagcag 1560  
tcggcgacac cgattttata aataaactga gcaccttctt tttaaacaaa caaatgcggg 1620  
tttatttctc agatgatgtt catccgtgaa tgggtccaggg aaggacctt cacttgact 1680  
atatggcatt atgtcatcac aagctctgag gcttctcctt tccatcctgc gtggacagct 1740  
aagacctcag ttttcaatag catctagagc agtgggactc agctgggggtg atttcgcccc 1800  
ccatctcgg gggaatgtct gaagacaatt ttggttacct caatgaggga gtggaggagg 1860  
atacagtgt actaccaact agtggataaa ggccagggat gctgctcaac ctctaccat 1920  
gtacaggacg tctccccatt acaactaccc aatccgaagt gtcaactgtg tcaggactaa 1980  
gaaaccctgg ttttgagtag aaaagggcct ggaaagaggg gagccaacaa atctgtctgc 2040  
ttctcacatt agtcattggc aaataagcat tctgtctctt tggctgctgc ctgagcacag 2100  
agagccagaa ctctatcggg caccaggata acatctctca gtgaacagag ttgacaaggc 2160  
ctatgggaaa tgcctgatgg gattatcttc agcttgttga gcttctaagt ttctttccct 2220  
tcattctacc ctgcaagcca agttctgtta gagaaatgcc tgagttctag ctgaggtttt 2280  
cttactctga atttagatct ccagaccctt cctggccaca attcaaatta aggcaacaaa 2340  
catatacctt ccatgaagca cacacagact tttgaaagca aggacaatga ctgcttgaat 2400  
tgaggccttg aggaatgaag ctttgaagga aaagaatact ttgtttccag ccccttccc 2460  
acactcttca tgtgttaacc actgccttcc tggaccttg agccacggtg actgtattac 2520  
atgttgttat agaaaactga ttttagagtt ctgatcgttc aagagaatga ttaaatatac 2580  
atttctt 2587

&lt;210&gt; 2

&lt;211&gt; 2070

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

cacagagaga ggcagcagct tgctcagcgg acaaggatgc tgggcgtgag ggaccaaggc 60  
ctgccctgca ctggggcctc ctccagccag tgctgaccag ggacttctga cctgctggcc 120  
agccaggacc tgtgtgggga ggccctcctg ctgccttggg gtgacaatct cagctccagg 180  
ctacaggag accgggagga tcacagagcc agcatgttac aggatcctga cagtgtacaa 240  
cctctgaaca gcctcgatgt caaacccctg cgcaaacccc gtatcccat ggagaccttc 300  
agaaaaggtg ggatcccat catcatagca ctactgagcc tggcgagtat catcattgtg 360  
gttgtcctca tcaaggtgat tctggataaa tactacttcc tctgcgggca gcctctccac 420  
ttcatcccga ggaagcagct gtgtgacgga gagctggact gtcccttggg ggaggacgag 480  
gagcactgtg tcaagagctt cccgaaggg cctgcagtgg cagtcgcct ctccaaggac 540  
cgatccacac tgcagggtgt ggactcggcc acagggaact ggttctctgc ctgtttcgac 600  
aacttcacag aagctctcgc tgagacagcc tgtaggcaga tgggtacag cagcaaacc 660  
actttcagag ctgtggagat tggcccagac caggatctgg atgttgttga aatcacagaa 720  
aacagccagg agcttcgcat gcggaactca agtgggccct gtctctcagg ctccctggtc 780  
tccttgact gtcttgctg tgggaagagc ctgaagaccc cccgtgtggt ggggtgggag 840  
gaggcctctg tggattcttg gccttggcag gtcagcatcc agtacgacaa acagcacgtc 900  
tgtggaggga gcatacctgga ccccaactgg gtctcagcg gcagccact gcttcaggaa 960

THIS PAGE BLANK (USPTO)




```

acataaccgat gtgttcaact ggaaggtgcg ggcaggctca gacaaactgg gcagcttccc 1020
atccctggct gtggccaaga tcatcatcat tgaattcaac cccatgtacc ccaaagacaa 1080
tgacatcgcc ctcatgaagc tgcagttccc actcactttc tcaggcacag tcaggcccat 1140
ctgtctgccc ttctttgatg aggagctcac tccagccacc ccactctgga tcattggatg 1200
gggctttacg aagcagaatg gaggaagat gtctgacata ctgctgcagg cgtcagtcca 1260
ggtcattgac agcacacggt gcaatgcaga cgatgcgtac cagggggaag tcaccgagaa 1320
gatgatgtgt gcaggcatcc cggaaggggg tgtggacacc tgccagggtg acagtgggtg 1380
gcccctgatg taccaatctg accagtggca tgtggtgggc atcgttagct ggggctatgg 1440
ctgcgggggc ccgagcacc caggagtata caccaaggtc tcagcctatc tcaactggat 1500
ctacaatgtc tggaaggctg agctgtaatg ctgctgcccc ttgacagtgc tgggagccgc 1560
ttccttcctg cctgcccac ctggggatcc cccaaagtca gacacagagc aagagtcccc 1620
ttgggtacac ccctctgccc acagcctcag catttcttgg agcagcaaag ggcctcaatt 1680
cctataagag accctcgag cccagaggcg cccagaggaa gtcagcagcc ctagctcggc 1740
cacacttggt gctcccagca tcccaggag agacacagcc cactgaacaa ggtctcaggg 1800
gtattgctaa gccaaagaag aactttccca cactactgaa tggaagcagg ctgtcttgta 1860
aaagcccaga tcaactgtgg ctggagagga gaaggaaagg gtctgcgcca gccctgtccg 1920
tcttcacca tcccgaagcc tactagagca agaaaccagt tgtaataata aatgcactgc 1980
cctactgttg gtatgactac cgttacctac tgttgcatg ttattacagc tatggccact 2040
attattaaag agctgtgtaa catctctggc
2070

```

&lt;210&gt; 3

&lt;211&gt; 1709

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

agcagactca caccagaact acattccctg gccccctgcc tgtgtgcttc tggccaggcc 60
ttggttgcca agtctgacct gagaaaagga tctgcagaaa atcagactat gggatcactt 120
tgtttgtgca ttgggaatga cattctttcc caccacagga aaacctttgg gactttcaga 180
gacattgttg ctagccaacc acatggctcag cctcaaagtt gagaggctca gtaaccctcc 240
tatccctaga gaattccaaa gtgtggatgt aatttaacta gaaagccatt ggtgactatc 300
tgtgatcctc tggaagtatg ctatgttgtg tatatcttgc atccaaagcc agagggaacc 360
acaatgacta gtaaaacggt ggtctcaatg ccacttagc ctctgcctct gaatttgacc 420
atagtggcgt tcagctgata gagcgggaag aagaaatatg cattttttat gaaaaaataa 480
atatccaaga gaagatgaaa ctaaatggag aaattgaaat acatctactg gaagaaaaga 540
tccaattcct gaaaatgaag attgctgaga agcaaagaca aatttgtgtg acccagaaat 600
tactgccagc caagagggtcc ctggatgccg acctagctgt gctccaaatt cagttttcac 660
agtgtacaga cagaattaaa gacctggaga aacagttcgt aaagcctgat ggtgagaata 720
gagctcgctt ccttcaggg aaagatctga ccgaaaaaga aatgatccaa aaattagaca 780
agctggaact acaactggcc aagaaggagg agaagctgct ggagaaggat ttcattctatg 840
agcaggctct caggctcaca gacaggctct gcagcaaac tcagggtgc aagcaggaca 900
cactgctctt agccaagaag atgaatggct atcaaagaag gatcaaaaat gcaactgaga 960
aatgatggc tcttggtgct gagctgtcca tgaaacaagc cctaaccatt gaactccaaa 1020
aggaagtcag ggagaaagaa gacttcatct tcacttgcaa ttccaggata gaaaaaggtc 1080
tgccactcaa taaggaaatt gagaaagaat ggttgaaagt ccttcgagat gaagaaatgc 1140
acgccttggc catcgctgaa aagtctcagg agttcttggg agcagataat cgccagctgc 1200
ccaatggtgt ttacacaact gcagagcagc gtccgaatgc ctacatcca gaagcagatg 1260
ccactcttcc ttgcccacaa cttatggtg ctttggctcc ttttaaacc agtgaacctg 1320

```

THIS PAGE BLANK (USPTO)

gagccaatat gaggcacata aggaaacctg ttataaagcc agttgaaatc tgaatatgtg 1380  
 aacaaatcca ggcctctcaa ggaaaagact tcaaccaggc ttccttgtac ccacaggtga 1440  
 aaaatgtgag cataatactt ctaatatattat tgataagtaa ggtaaccaca attagtcagc 1500  
 aacagagtac aacagggttt ctatttacct accaactact atacctttca tgacgttgaa 1560  
 tgggacatag aactgtccta catttatgtc aaagtatata tttgaatcgc ttatattttc 1620  
 tttttcactc tttatattga gtacattcca gaaatttgta gtaggcaagg tgctataaaa 1680  
 atgcactaaa aataaatctg tttcaatg 1709

<210> 4

<211> 257

<212> DNA

<213> Homo sapiens

<400> 4

ttaatgggta agtatttttt atatgcttta gctatagcta aagaaaactg atacttaaca 60  
 aagttgaata gtattattca ctgggtgctcc taaaatattg tttttcagtg taaaatatgc 120  
 atatcttcta tatttaatat gaaagtcttg aaatgtatca gacagaaggg gatttcagtt 180  
 tgcaaataat gagcaatgta gcaattttta cacatttcat aaatatatat tttgtcattg 240  
 gtggagagca ccatttg 257

<210> 5

<211> 359

<212> DNA

<213> Homo sapiens

<400> 5

gcctgagagc acttagcggt catgagtgtc cccaccatgg cctggatgat gcttctcctc 60  
 ggactccttg cttatggatc aggtcaggga gtggattctc agactgtggt gacccaagag 120  
 ccacgttat cagtgtcccc tggagggaca gtcacactca cttgtggctt ggctcttgac 180  
 tcagtctcta ctaatttctt ccccaacctg taccagcaga ccccaggcca ggctccacgc 240  
 acgctcatct acagcacaag cactcgctct tctgggggtc ctgatcgtt ctctggctcc 300  
 atccttggga acaaagctgc cctcaccatt acgggggccc aggcagatga tgaatctga 359

<210> 6

<211> 1372

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (6)

<220>

<221> unsure

<222> (9)

<400> 6

ccttanagnc ttggttgcca aacagaatgc ccatatccgt cttacttgtg aggaagcttg 60

THIS PAGE BLANK (USPTO)




```

ccttggggcgc cctctgctgg ccctcctgaa gctaacaggg gcgagtgtctc ggtgggtttac 120
aaattgcctc catgcagact atgaaactgt tcagcctgct atagttagat ctctggcact 180
ggcccaggag gtcttgacaga tttgcagatc aaggagaacc caggagtttc aaagaagcgg 240
ctagtaaagg tctctgagat ccttgacta gctacatcct cagggtagga ggaagatggc 300
ttccagaagc atgcggctgc tctattgct gagctgctg gccaaaacag gagtccctggg 360
tgatatcatc atgagaccca gctgtgctcc tgggatggtt ttaccacaag tccaattgct 420
atggttactt caggaagctg aggaactggt ctgatgccga gctcgagtgt cagtcttacg 480
gaaacggagc ccacctggca tctatcctga gtttaaagga agccagcacc atagcagagt 540
acataagtgg ctatcagaga agccagccga tatggattgg cctgcacgac ccacagaaga 600
ggcagcagtg gcagtggatt gatggggcca tgtatctgta cagatcctgg tctggcaagt 660
ccatgggtgg gaacaagcac tgtgctgaga tgagctccaa taacaacttt ttaacttggg 720
gcagcaacga atgcaacaag cgccaacact tcctgtgcaa gtaccgacca tagagcaaga 780
atcaagattc tgctaactcc tgcacagccc cgctctcttc ctttctgcta gcctggctaa 840
atctgtcatc tatttcagag gggaaacctc gcaaaactaag agtgataagg gccctactac 900
actggctttt ttaggcttag agacagaaac ttttagcattg gcccagtagt ggcttctagc 960
tctaaatggt tgccccgcca tccctttcca cagtatectt ctccctcct cccctgtctc 1020
tggctgtctc gagcagtcta gaagagtgc tctccagcct atgaaacagc tgggtctttg 1080
gccataagaa gtaaagattt gaagacagaa ggaagaaact caggagtaag cttctagccc 1140
ccttcagctt ctacaccctt ctgccctctc tccattgcct gcacccacc ccagccactc 1200
aactcctgct tgttttctc ttggccatgg gaagggtttac cagtagaatc cttgctaggt 1260
tgatgtgggc catacattcc ttttaataaac cattgtgtac ataagaggtt gctgtgttcc 1320
agttcagtaa atggtgaatg tggaaaagtg aaataagacc aagaaataca aa 1372

```

&lt;210&gt; 7

&lt;211&gt; 291

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (277)

&lt;400&gt; 7

```

agaatggtag tagtaagaag aagaaaaata gaggatctga atgtattttg aaggtagagt 60
ccactggact tagagatgga ttgaatgtgg aagattaagg aaagggagaa atgaaagata 120
gtcttaggtt tcactctcag atgactgggt gaacagcagt gttctttgct aagatgggga 180
agactaggga aaagagccag ttctgtattg agcatattat atttaagaca atcccatctg 240
ggtccaaaga caatgttgat ttttttctt agatacntgc ctttagacc t 291

```

&lt;210&gt; 8

&lt;211&gt; 1275

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (410)

THIS PAGE BLANK (USPTO)



&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (728)..(756)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (957)

&lt;400&gt; 8

```

attctagaac atatgtataa gctaaaaaca gtatcttact cagatcagta gttatcgtgt 60
ctatcagcta taaaaaaaaat caactgccag ccaagaactt taaaacttta agctgtgtat 120
tatagaaccg ttttgtgtag cattggaata ttgtccattt tgtaagtcac tgtgaatgtt 180
cttaattatc agcttgaagg tatttttgta ttaaaagttg acattgaaga acctaaagtg 240
atgatgggat ttggggccag tagtgaaagt atgtttcctc taaaatattt ccctaaacag 300
tggtatacat gggtattttta ttatgagatt tgtatatgtt ctgtgtttct ctgtgaacaa 360
tgtttcagtc tctctgtcac catatgtaag gggaggtcca caaatatagn actacattgc 420
acaaaactaa aattgttaat tacaagaaaa tatagggtgt taccttttga aggtttatta 480
atacatatgg ttgtcacaat acgtatatat gataaatggg gtacatatac agatgtttat 540
ggtgtataaa tttttctata cccaattaga attatcttcc tgattcttta ttcaataaca 600
tgctaattcc tcttctatgt tctatagtga cagaatgcta acttttctta taccctggca 660
gaggacagag gagtctgggc taggatgggg aactgaattt ttgaacgaaa aggaaagaga 720
aaggatgnnn nnnnnnnnnn nnnnnnnnnn nnnnnntaat gtttcttagt ctttttgatt 780
ggccatttga acagtctaca agtttaacgt tatttccagt gaagtaggat ggctgacctt 840
gcaatacatg tttcttcaaa agggtaaaaa tgcttttagt acctaaagct aaattttgta 900
catttgacat caggggtgtt ataagtactg cacttaatac aaagctattt ctcaatngtg 960
ttatttttga gacaaatttt tcttcaccaa taacttcttg ttggtagctt tttgttttgt 1020
aaaaattgag agatggcaat gcttatctca accagattat ccatctgcag aattaaggta 1080
tgcaactggt aaataaaaga caaatgctcc agtttgtctt tctcaacctt tgagttctta 1140
acctttgagt taaaacctag tctaaatagt gggaatgtct tggtttacag taagggtttc 1200
ttgggaagga tcttggtttt gtgatctatt tgtgaattaa ggagtagatg ttaaccatta 1260
ttttatagat aagtg

```

&lt;210&gt; 9

&lt;211&gt; 2479

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```

gtcatattga acattccaga tacctatcat tactcgatgc tgttgataac agcaagatgg 60
ctttgaactc agggtcacca ccagctattg gaccttacta tgaaaaccaa ggataccaac 120
cggaaaaccc ctatcccgca cagcccactg tgggtccccc tgtctacgag gtgcatccgg 180
ctcagtacta cccgtccccc gtgccccagt acgccccgag ggtcctgacg caggcttcca 240
accccgctcg ctgcacgcag cccaaatccc catccgggac agtgtgcacc tcaaagacta 300
agaaagcact gtgcatcacc ttgaccttg ggaccttct cgtgggagct gcgctggccg 360
ctggcctact ctggaagtgc atgggcagca agtgctccaa ctctgggata gagtgcgact 420
cctcaggtag ctgcatcaac cctctaact ggtgtgatgg cgtgtcacac tgccccggcg 480
gggaggacga gaatcggtgt gtcgcctct acggacacaa cttcatcctt cagatgtact 540
catctcagag gaagtctctg caccctgtgt gccaaagcga ctggaacgag aactacgggc 600

```

THIS PAGE BLANK (USPTO)

gggcgggcctg cagggacatg ggctataaga ataattttta ctctagccaa ggaatagtgg 660  
 atgacagcgg atccaccagc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720  
 ataaaaaact gtaccacagt gatgcctgtt cttcaaaagc agtggtttct ttacgctgtt 780  
 tagcctgctg ggtcaacttg aactcaagcc gccagagcag gatcgtgggc ggtgagagcg 840  
 cgctcccggg ggctggccc tggcaggtca gcctgcacgt ccagaacgtc cacgtgtgctg 900  
 gaggtcccat catcaccccc gagtggatcg tgacagccgc ccactgctg gaaaaacctc 960  
 ttaacaatcc atggcattgg acggcatttg cggggatttt gagacaatct ttcattgttct 1020  
 atggagccgg ataccaagta caaaaagtga tttctcatcc aaattatgac tccaagacca 1080  
 agaacaatga cattgcgctg atgaagctgc agaagcctct gactttcaac gacctagtga 1140  
 aaccagtgtg tctgccaac ccaggcatga tgctgcagcc agaacagctc tgctggattt 1200  
 ccgggtgggg ggccaccgag gagaaaggga agacctcaga agtgctgaac gctgccagg 1260  
 tgcttctcat tgagacacag agatgcaaca gcagatatgt ctatgacaac ctgatcacac 1320  
 cagccatgat ctgtgccggc ttcttgcagg ggaacgtcga ttcttgccag ggtgacagt 1380  
 gagggcctct ggtcacttcg aacaacaata tctggtggct gataggggat acaagctggg 1440  
 gttctggctg tgccaaagct tacagaccag gagtgtacgg gaatgtgat gtattcacgg 1500  
 actggattta tcgacaaatg aaggcaaacg gctaattccac atggtcttcg tccttgacgt 1560  
 cgttttacaa gaaaacaatg gggctgggtt tgcttccccg tgcatgattt actcttagag 1620  
 atgattcaga ggtcacttca tttttattaa acagtgaact tgtctggctt tggcactctc 1680  
 tgccatactg tgcaggctgc agtggctccc ctgccagcc tgctctccct aacccttgt 1740  
 ccgcaagggg tgatggccgg ctggttgtgg gcaactggcg tcaattgtgg aaggaagagg 1800  
 gttggaggct gccccattg agatcttctt gctgagtcct ttccaggggc caattttgga 1860  
 tgagcatgga gctgtcactt ctcagctgct ggatgacttg agatgaaaaa ggagagacat 1920  
 ggaaagggag acagccaggt ggcacctgca gcggtgccc tctggggcca cttggtagt 1980  
 tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040  
 gatggtggcc agaaataaag ggaccagccc ttcattgggtg gtgacgtggt agtcacttgt 2100  
 aaggggaaca gaaacatttt tgttcttatg ggtgagaat atagacagt cccttggtgc 2160  
 gaggggaagca attgaaaagg aacttgccct gacgactcct ggtgcaggtc tccacctgca 2220  
 cattgggtgg ggctcctggg agggagactc agccttctc ctcactctcc ctgacctgc 2280  
 tctagcacc ctggagagt aatgccctt ggtccctggc agggcgccaa gtttggcacc 2340  
 atgtcggcct cttcaggcct gatagtcatt ggaaattgag gtccatgggg gaaatcaagg 2400  
 atgctcagtt taaggtacac tgtttccatg ttatgtttct acacattgat ggtggtgacc 2460  
 ctgagttcaa agccatctt 2479

&lt;210&gt; 10

&lt;211&gt; 576

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

ttcaaagaca tattagaagt tgggaaaata attcatgtga actagacaag tgtgttaaga 60  
 gtgataagta aaatgcacgt ggagacaagt gcatccccag atctcaggga cctccccctg 120  
 cctgtcacct ggggagttag aggacaggat agtgcattgt ctttgtctct gaatttttag 180  
 ttatatgtgc tgtaatgttg ctctgaggaa gccctggaa agtctatccc aacatatcca 240  
 catcttatat tccacaaatt aagctgtagt atgtacccta agacgctgct aattgactgc 300  
 cacttcgcaa ctcaggggcg gctgcatttt agtaatgggt caaatgattc actttttatg 360  
 atgcttccaa aggtgccttg gcttctcttc ccaactgaca aatgccaaag ttgagaaaaa 420  
 tgatcataat tttagcataa acagagcagt cggcgacacc gattttataa ataaactgag 480  
 caccttcttt ttaaacaac aaatgcgggt ttatttctca gatgatgttc atccgtgaat 540

THIS PAGE BLANK (USPTO)

gggccaggggaggacctttc accttgacta tatggc

576

<210> 11

<211> 890

<212> DNA

<213> Homo sapiens

<400> 11

```

caagctctga ggcttctcct ttccatcctg cgtggacagc taagacctca gttttcaata 60
gcatctagag cagtgggact cagctggggt gatttcgccc cccatctccg ggggaatgtc 120
tgaagacaat tttggttacc tcaatgaggg agtggaggag gatacagtc tactaccaac 180
tagtggataa aggccaggga tgctgctcaa cctcctacca tgtacaggga cgtctcccca 240
ttacaactac ccaatccgaa gtgtcaactg tgtcaggact aagaaaccct ggttttgagt 300
agaaaagggc ctggaaagag gggagccaac aaatctgtct gcttcctcac attagtcatt 360
ggcaaataag cattctgtct ctttggtgct gcctcagca cagagagcca gaactctatc 420
gggcaccagg ataactctc tcagtgaaca gagttgacaa ggcctatggg aaatgcctga 480
tgggattatc ttcagcttgt tgagcttcta agtttctttc ccttcattct accctgcaag 540
ccaagtcttg taagagaaat gcctgagttc tagctcaggt tttcttactc tgaatttaga 600
tctccagacc cttcctggcc acaattcaaa ttaaggcaac aaacatatac cttccatgaa 660
gcacacacag acttttgaaa gcaaggacaa tgactgcttg aattgaggcc ttgaggaatg 720
aagctttgaa ggaaaagaat actttgtttc cagccccctt cccacactct tcatgtgtta 780
accactgcct tcttgacct tggagccacg gtgactgtat tacatgttgt tatagaaaac 840
tgatttttaga gttctgatcg ttcaagagaa tgattaaata tacatttctc 890

```

<210> 12

<211> 406

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (30)

<220>

<221> unsure

<222> (248)

<220>

<221> unsure

<222> (383)

<400> 12

```

gtgaatgtgg actataatgc cagctcagan accttgcggt gtgaggctcc ccgatggttc 60
ccccagccca cagtggctctg ggcattccaa gttgaccagg gagccaactt ctcggaagtc 120
tccaatacca gctttgagct gaactctgag aatgtgacca tgaagggtgt gtctgtgtc 180
tacaatgtta cgatcaacaa cacatactcc tgtatgattg aaaatgacat tgccaaagca 240
acaggggnta tcaaagtgc agaatcggag atcaaaaaggc ggagtcacct acagctgcta 300
aactcaaagg cttctctgtg tgtctcttct ttctttgcca tcagctgggc acttctgcct 360

```

THIS PAGE BLANK (USPTO)

ctcagccctt acctgatgct aanataatgt gccttgcca caaaaa

406

&lt;210&gt; 13

&lt;211&gt; 462

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

ggaaggcagc ggcagctcca ctcagccagt accagatac gctgggaacc ttccccagcc 60  
 atggcttccc tggggcagat cctcttctgg agcataatta gcatcatcat tattctggct 120  
 ggagcaattg cactcatcat tggctttggt atttcaggga gacactccat cacagtcact 180  
 actgtgcct cagctgggaa cattggggag gatggaatcc tgagctgcac ttttgaacct 240  
 gacatcaaac tttctgatat cgtgatacaa tggctgaagg aaggtgtttt aggcttggtc 300  
 catgagttca aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagaggcccg 360  
 acagcagtggt ttgctgatca agtgatagtt ggcaatgcct ctttgccggt gaaaaacgtg 420  
 caactcacag atgctggcac ctacaaatgt tatatcatca ct 462

&lt;210&gt; 14

&lt;211&gt; 272

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

gcagcttgct cagcggacaa ggatgctggg cgtgaggag caaggcctgc cctgcactcg 60  
 ggctcctcc agccagtgt gaccaggagc ttctgacctg ctggccagcc aggacctgtg 120  
 tggggaggcc ctctgctgc cttgggtga caatctcage tccaggctac agggagaccg 180  
 ggaggatcac agagccagca tggatcctga cagtgatcaa cctctgaaca gcctcgtcaa 240  
 ggtgattctg gataaatact acttcctctg cg 272

&lt;210&gt; 15

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu  
 1 5 10 15

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val  
 20 25 30

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro  
 35 40 45

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val  
 50 55 60

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys

THIS PAGE BLANK (USPTO)



10

THIS PAGE BLANK (USPTO)

325 330 335  
 Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln  
 340 345 350  
 Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn  
 355 360 365  
 Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp  
 370 375 380  
 Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala  
 385 390 395 400  
 Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr  
 405 410 415  
 Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly  
 420 425 430  
 Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser  
 435 440 445  
 Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly  
 450 455 460  
 Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe  
 465 470 475 480  
 Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly  
 485 490

THIS PAGE BLANK (USPTO)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C07K 16/8

US CL : 435/6, 7.1, 7.92; 530/387.1, 388.85

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 7.92; 530/387.1, 388.85

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
SEQ ID NO's 1-5 and 9-14

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Medline, CAPLUS, GenEmbl, N-Geneseq, USPATFULL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,939,258 A (CROCE et al) 17 August 1999, see col. 3, lines 1-22.	1-3
---P		---
Y		4,5
X	US 5,733,748 A ( YU et al) 31 March 1998, see abstract.	1-3
---		---
Y		4, 5

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
22 NOVEMBER 1999

Date of mailing of the international search report

7 FEB 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

LARRY HELMS

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/19655

**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p><b>PAOLONI-GIACOBNO et al. Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCR Domains and Maps to 21q22.3. Genomics. 1997, Vol. 44, pages 309-320, especially page 311.</b></p>	1-9

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-9

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19655

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

Group I, claim(s) 1-9, drawn to an in vitro method for diagnosing the presence of cancer by measuring the CSG levels in a patient with an antibody against CSG.

Group II, claim(s) 10-11, drawn to a method of in vivo imaging a selected cancer by administering an antibody with a paramagnetic ion or radioisotope label to the patient.


Group III, claim(s) 12-13, drawn to a method of in vivo treating a cancer in a patient comprising administering an antibody conjugated to a cytotoxic agent.

The inventions listed as Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The method of Group I recites the special technical feature of an in vitro diagnostic method to measure CSG levels that are not found in Groups II and III. The method of Group II recites the special technical features of an in vivo imaging method that is not found in Groups I and III. The method of Group III recites the special technical feature of in vivo treating a cancer using a cytotoxic agent that is not found in Groups I and II. Therefore, inventions of Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1.



# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY



PCT

WRITTEN OPINION

(PCT Rule 66)

To: JANE MASSEY LICATA  
LAW OFFICES OF JANE MASSEY LICATA  
66 E. MAIN STREET  
MARLTON NJ 08053

Docket System ☒  
Status Report ☒  
Docket Book ☒

8/16/00 ANS

Date of Mailing  
(day/month/year)

16 JUN 2000

Applicant's or agent's file reference  
DEX-0043

REPLY DUE within TWO months  
from the above date of mailing

International application No.  
PCT/US99/19655

International filing date (day/month/year)  
01 SEPTEMBER 1999

Priority date (day/month/year)  
02 SEPTEMBER 1998

International Patent Classification (IPC) or both national classification and IPC  
IPC(7): C12Q 1/68; C07K 16/8 and US Cl.: 435/6, 7.1, 7.92; 530/387.1, 388.85

Applicant  
DIADEXUS LLC

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

When? See the time limit indicated above. ~~The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(4).~~

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 02 JANUARY 2001

Name and mailing address of the IPEA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LARRY HELMS

Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)

## 1. Basis of the opinion

1. With regard to the **elements** of the international application:\*

- ☒ the international application as originally filed
- ☒ the description:  
pages 1-38, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the claims:  
pages 39-41, as originally filed  
pages NONE, as amended (together with any statement) under Article 19  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the drawings:  
pages NONE, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the sequence listing part of the description:  
pages NONE, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".

THIS PAGE BLANK (USPTO)

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 10-13

because:

☐ the said international application, or the said claim Nos. \_ relate to the following subject matter which does not require international preliminary examination (*specify*).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_ are so unclear that no meaningful opinion could be formed (*specify*).

☐ the claims, or said claims Nos. \_ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 10-13.

2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

THIS PAGE BLANK (USPTO)

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. statement**

Novelty (N)	Claims <u>4-9</u>	YES
	Claims <u>1-3</u>	NO
Inventive Step (IS)	Claims <u>6-9</u>	YES
	Claims <u>1-5</u>	NO
Industrial Applicability (IA)	Claims <u>1-9</u>	YES
	Claims <u>NONE</u>	NO

**2. citations and explanations**

Claims 1-3 lack novelty under PCT Article 33(2) as being anticipated by Yu et al., U.S. Patent 5,733,748, . 31 MARCH 1998.

a. The claims recite a method for diagnosing/diagnosing metastasis/staging the presence of a selected cancer in a patient comprising measuring levels of CSG in the patient and comparing the measured levels to normal samples. The term "staging" is being interpreted as metastasis of the cancer.

b. Yu et al teach a method for diagnosing/diagnosing metastasis/staging the presence of a colon specific gene "CSG" by measuring the levels of CSG in the patient, whereby an elevated level indicates the presence of cancer (see abstract, column 2, lines 30-35 and 41-42). Thus, claims 1-3 lack novelty under PCT Article 33(2).

Claims 4-5 lack an inventive step under PCT Article 33(3) as being obvious over Yu et al.

a. The claims recite a method of monitoring a selected cancer in a patient for the onset of metastasis or change in stage of the cancer by periodically measuring levels of CSG in a patient and comparing the measured levels with measured levels in normal controls. The term "stage" has been interpreted to include metastasis.

b. Yu et al has been described supra. It would have been obvious to one of ordinary skill in the art to periodically monitor a cancer patient for metastasis or the stage of the cancer. Thus, claims 4-5 lack an inventive step under PCT Article 33(3).

Claims 6-9 meet the criteria set out in PCT Article 33(3), because the prior art does not teach or fairly suggest a cancer specific gene comprising SEQ ID Nos 1, 2, 3, 9, 10, 11, 12, 13, or 14, or an antibody directed against a CSG wherein the CSG comprises SEQ ID Nos 1, 2, 3, 9, 10, 11, 12, 13, or 14.

----- NEW CITATIONS -----

NONE

THIS PAGE BLANK (USPTO)



WRITTEN OPINION

International application No.

PCT/US99/19655

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**TIME LIMIT:**


The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

THIS PAGE BLANK (USPTO)

PATENT COOPERATION TREATY  
PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference DEX-0043	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/19655	International filing date (day/month/year) 01 SEPTEMBER 1999	Priority date (day/month/year) 02 SEPTEMBER 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): C12Q 1/68; C07K 16/8 and US Cl.: 435/6, 7.1, 7.92; 530/387.1, 388.85		
Applicant DIADEXUS LLC		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  29 MARCH 2000	Date of completion of this report  02 JANUARY 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  LARRY R. HELMS
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/19655

**I. Basis of the report****1. With regard to the elements of the international application:\***

- ☒ the international application as originally filed
- ☒ the description:  
pages 1-38 , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_
- ☒ the claims:  
pages 39-41 , as originally filed  
pages NONE , as amended (together with any statement) under Article 19  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_
- ☒ the drawings:  
pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_
- ☒ the sequence listing part of the description:  
pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**

- ☒ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☒ The amendments have resulted in the cancellation of:**

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

THIS PAGE BLANK (USPTO)

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 10-13

because:

☐ the said international application, or the said claim Nos. \_ relate to the following subject matter which does not require international preliminary examination (*specify*).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_ are so unclear that no meaningful opinion could be formed (*specify*).

☐ the claims, or said claims Nos. \_ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 10-13.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

THIS PAGE BLANK (USPTO)



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/19655

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

## 1. statement

Novelty (N)	Claims <u>4-9</u>	YES
	Claims <u>1-3</u>	NO
Inventive Step (IS)	Claims <u>6-9</u>	YES
	Claims <u>1-5</u>	NO
Industrial Applicability (IA)	Claims <u>1-9</u>	YES
	Claims <u>NONE</u>	NO

## 2. citations and explanations (Rule 70.7)

Claims 1-3 lack novelty under PCT Article 33(2) as being anticipated by Yu et al (U.S. Patent 5,733,748, issued 3/31/98).

a. The claims recite a method for diagnosing/diagnosing metastasis/staging the presence of a selected cancer in a patient comprising measuring levels of CSG in the patient and comparing the measured levels to normal samples. The term "staging" is being interpreted as metastasis of the cancer.

b. Yu et al teach a method for diagnosing/diagnosing metastasis/staging the presence of a colon specific gene "CSG" by measuring the levels of CSG in the patient, whereby an elevated level indicates the presence of cancer (see abstract, column 2, lines 30-35 and 41-42). Thus, claims 1-3 lack novelty under PCT Article 33(2).

Claims 4-5 lack an inventive step under PCT Article 33(3) as being obvious over Yu et al.

a. The claims recite a method of monitoring a selected cancer in a patient for the onset of metastasis or change in stage of the cancer by periodically measuring levels of CSG in a patient and comparing the measured levels with measured levels in normal controls. The term "stage" has been interpreted to include metastasis.

b. Yu et al has been described supra. It would have been obvious to one of ordinary skill in the art to periodically monitor a cancer patient for metastasis or the stage of the cancer. Thus, claims 4-5 lack an inventive step under PCT Article 33(3).

Claims 6-9 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a cancer specific gene comprising SEQ ID Nos 1, 2, 3, 9, 10, 11, 12, 13, or 14, or an antibody directed against a CSG wherein the CSG comprises SEQ ID Nos 1, 2, 3, 9, 10, 11, 12, 13, or 14.

Claims 1-9 meet the criteria set out under PCT Article 33(4).

----- NEW CITATIONS -----

NONE

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/19655

**Supplemental Box**


(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

THIS PAGE BLANK (USPTO)

# PATENT COOPERATION TREATY



From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: JANE MASSEY LICATA  
LAW OFFICES OF JANE MASSEY LICATA  
66 E. MAIN STREET  
MARLTON NJ 08053

Docket System ☒  
Status Report ☒  
Docket Book ☒  
NP= 3-2-01

## NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing  
(day/month/year)

25 JAN 2001

Applicant's or agent's file reference  
DEX-0043

### IMPORTANT NOTIFICATION

International application No.  
PCT/US99/19655

International filing date (day/month/year)  
01 SEPTEMBER 1999

Priority Date (day/month/year)  
02 SEPTEMBER 1998

Applicant  
DIADEXUS LLC

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LARRY R. HELMS

Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference DEX-0043	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/19655	International filing date (day/month/year) 01 SEPTEMBER 1999	Priority date (day/month/year) 02 SEPTEMBER 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): C12Q 1/68; C07K 16/8 and US Cl.: 435/6, 7.1, 7.92; 530/387.1, 388.85		
Applicant DIADEXUS LLC		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  29 MARCH 2000	Date of completion of this report  02 JANUARY 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  LARRY R. HELMS
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/19655

## I. Basis of the report

1. With regard to the **elements** of the international application:\*☒ the international application as originally filed☒ the description:

pages 1-38 , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the claims:

pages 39-41 , as originally filed  
pages NONE , as amended (together with any statement) under Article 19  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the drawings:

pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

☒ the sequence listing part of the description:

pages NONE , as originally filed  
pages NONE , filed with the demand  
pages NONE , filed with the letter of \_\_\_\_\_

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  
These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:☒ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. ☒ The amendments have resulted in the cancellation of:☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.  
PCT/US99/19655

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 10-13

because:

☐ the said international application, or the said claim Nos. \_ relate to the following subject matter which does not require international preliminary examination (*specify*).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_ are so unclear that no meaningful opinion could be formed (*specify*).

☐ the claims, or said claims Nos. \_ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 10-13.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/19655

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. statement

Novelty (N)	Claims <u>4-9</u>	YES
	Claims <u>1-3</u>	NO
Inventive Step (IS)	Claims <u>6-9</u>	YES
	Claims <u>1-5</u>	NO
Industrial Applicability (IA)	Claims <u>1-9</u>	YES
	Claims <u>NONE</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-3 lack novelty under PCT Article 33(2) as being anticipated by Yu et al (U.S. Patent 5,733,748, issued 3/31/98).

a. The claims recite a method for diagnosing/diagnosing metastasis/staging the presence of a selected cancer in a patient comprising measuring levels of CSG in the patient and comparing the measured levels to normal samples. The term "staging" is being interpreted as metastasis of the cancer.

b. Yu et al teach a method for diagnosing/diagnosing metastasis/staging the presence of a colon specific gene "CSG" by measuring the levels of CSG in the patient, whereby an elevated level indicates the presence of cancer (see abstract, column 2, lines 30-35 and 41-42). Thus, claims 1-3 lack novelty under PCT Article 33(2).

Claims 4-5 lack an inventive step under PCT Article 33(3) as being obvious over Yu et al.

a. The claims recite a method of monitoring a selected cancer in a patient for the onset of metastasis or change in stage of the cancer by periodically measuring levels of CSG in a patient and comparing the measured levels with measured levels in normal controls. The term "stage" has been interpreted to include metastasis.

b. Yu et al has been described supra. It would have been obvious to one of ordinary skill in the art to periodically monitor a cancer patient for metastasis or the stage of the cancer. Thus, claims 4-5 lack an inventive step under PCT Article 33(3).

Claims 6-9 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a cancer specific gene comprising SEQ ID Nos 1, 2, 3, 9, 10, 11, 12, 13, or 14, or an antibody directed against a CSG wherein the CSG comprises SEQ ID Nos 1, 2, 3, 9, 10, 11, 12, 13, or 14.

Claims 1-9 meet the criteria set out under PCT Article 33(4).

----- NEW CITATIONS -----

NONE

THIS PAGE BLANK (USPTO)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/19655

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

THIS PAGE BLANK (USPTO)



## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 17 May 2000 (17.05.00)	
<b>International application No.</b> PCT/US99/19655	<b>Applicant's or agent's file reference</b> DEX-0043
<b>International filing date</b> (day/month/year) 01 September 1999 (01.09.99)	<b>Priority date</b> (day/month/year) 02 September 1998 (02.09.98)
<b>Applicant</b> SALCEDA, Susana et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
29 March 2000 (29.03.00)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer Olivia RANAIVOJAONA</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

**THIS PAGE BLANK (USPTO)**